Overview

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Status:
Completed

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

This multicenter, open-label, phase II trial aims to assess the safety and efficacy of palbociclib in adult patients with Oligodendroglioma or recurrent oligoastrocytoma anaplastic with the activity of the protein RB preserved.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Investigación en Neurooncología

Collaborator:

Pfizer

Treatments:

Palbociclib